cysteine has been researched along with oxidopamine in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Correa, JG; Stoppani, AO | 1 |
| Hermida-Ameijeiras, A; Labandeira-Garcia, JL; Méndez-Alvarez, E; Muñoz-Patiño, AM; Soto-Otero, R | 1 |
| Charlton, CG; Lamango, NS | 1 |
| Hermida-Ameijeiras, A; Labandeira-García, JL; López-Martín, ME; Méndez-Alvarez, E; Soto-Otero, R | 1 |
| Hermida-Ameijeiras, A; Labandeira-García, JL; López-Real, AM; Méndez-Alvarez, E; Soto-Otero, R | 1 |
| Bar-Am, O; Fridkin, M; Gal, S; Warshawsky, A; Weiner, LM; Youdim, MB; Zheng, H | 1 |
| Diaz-Muñoz, M; Garcia, E; Giordano, M; Herrera-Mundo, MN; Limon, D; Maldonado, PD; Pedraza-Chaverri, J; Perez-De La Cruz, V; Santamaria, A | 1 |
| Ali, SF; Cuadrado, A; Cuevas, E; González-Trujano, ME; Macías-Silva, M; Maldonado, PD; Pedraza-Chaverrí, J; Santamaría, A; Tobón-Velasco, JC; Vázquez-Victorio, G | 1 |
| Haining, RL; Hernandez, A; Jones, TM | 1 |
| Chohan, K; Farzam, A; Hewitt, SJ; Özcelik, D; Park, DS; Pezacki, JP; Strmiskova, M | 1 |
| Bartosz, G; Pieńkowska, N; Sadowska-Bartosz, I | 1 |
11 other study(ies) available for cysteine and oxidopamine
| Article | Year |
|---|---|
Catecholamines enhance dihydrolipoamide dehydrogenase inactivation by the copper Fenton system. Enzyme protection by copper chelators.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Binding Sites; Captopril; Catecholamines; Catechols; Cattle; Chelating Agents; Copper; Cysteine; Dihydrolipoamide Dehydrogenase; Dopamine; Epinephrine; Hydrogen Peroxide; Hydroxyl Radical; Iron; Kinetics; Mammals; Norepinephrine; Oxidation-Reduction; Oxidopamine; Penicillamine | 1996 |
Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease.
Topics: Acetylcysteine; Animals; Antioxidants; Ascorbic Acid; Cysteine; Female; Free Radical Scavengers; Glutathione; Hydrogen Peroxide; Neurons; Oxidation-Reduction; Oxidopamine; Oxygen Consumption; Parkinson Disease; Rats; Rats, Sprague-Dawley; Sympatholytics | 2000 |
Farnesyl-L-cysteine analogs block SAM-induced Parkinson's disease-like symptoms in rats.
Topics: Amphetamine; Animals; Central Nervous System Stimulants; Chromatography, Gel; Cysteine; Freeze Drying; Male; Methylation; Motor Activity; Nerve Tissue Proteins; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; S-Adenosylmethionine; Stereotyped Behavior; Sympathectomy, Chemical; Tremor | 2000 |
Effect of iron and manganese on hydroxyl radical production by 6-hydroxydopamine: mediation of antioxidants.
Topics: Acetylcysteine; Animals; Antioxidants; Ascorbic Acid; Corpus Striatum; Cysteine; Female; Glutathione; Hydrogen Peroxide; Hydroxyl Radical; Iron; Manganese; Oxidation-Reduction; Oxidopamine; Rats; Rats, Sprague-Dawley | 2001 |
Effects of aluminum and zinc on the oxidative stress caused by 6-hydroxydopamine autoxidation: relevance for the pathogenesis of Parkinson's disease.
Topics: Adrenergic Agents; Aluminum; Animals; Antioxidants; Ascorbic Acid; Brain; Cations; Cysteine; Glutathione; Hydroxyl Radical; Male; Mitochondria; Oxidative Stress; Oxidopamine; Oxygen Consumption; Polarography; Rats; Rats, Sprague-Dawley; Spectrophotometry; Thiobarbituric Acid Reactive Substances; Zinc | 2002 |
Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition.
Topics: Animals; Antioxidants; Cell Survival; Culture Media, Serum-Free; Cysteine; Designer Drugs; Hydroxyl Radical; Hydroxyquinolines; Iron Chelating Agents; Lipid Peroxidation; Monoamine Oxidase Inhibitors; Neurodegenerative Diseases; Neuroprotective Agents; Oxidopamine; PC12 Cells; Piperazines; Rats | 2005 |
Lipid peroxidation, mitochondrial dysfunction and neurochemical and behavioural deficits in different neurotoxic models: protective role of S-allylcysteine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Basal Ganglia; Behavior, Animal; Biomarkers; Cysteine; Disease Models, Animal; Dopamine; Lipid Peroxidation; Male; Mice; Mice, Inbred C57BL; Mitochondria; Motor Activity; MPTP Poisoning; Neuroprotective Agents; Neurotoxicity Syndromes; Nitro Compounds; Oxidative Stress; Oxidopamine; Propionates; Rats; Rats, Wistar; Synaptosomes; Time Factors | 2008 |
RETRACTED: S-allyl cysteine protects against 6-hydroxydopamine-induced neurotoxicity in the rat striatum: involvement of Nrf2 transcription factor activation and modulation of signaling kinase cascades.
Topics: Animals; Cysteine; JNK Mitogen-Activated Protein Kinases; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neostriatum; NF-E2-Related Factor 2; Oxidopamine; PC12 Cells; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar; Signal Transduction; Tumor Cells, Cultured | 2012 |
Saturation Binding of Nicotine to Synthetic Neuromelanin Demonstrated by Fluorescence Spectroscopy.
Topics: Caffeine; Cysteine; Dopamine; Iron; Melanins; Nicotine; Oxidopamine; Parkinson Disease; Polymerization; Spectrometry, Fluorescence | 2016 |
A functionalized hydroxydopamine quinone links thiol modification to neuronal cell death.
Topics: Animals; Cell Line; Cell Survival; Cycloaddition Reaction; Cysteine; Disease Models, Animal; Dopaminergic Neurons; Down-Regulation; Female; Humans; Hydroxydopamines; Male; Mass Spectrometry; Mice; Oxidopamine; Parkinson Disease; Protein Disulfide-Isomerases; Proteomics; Sulfhydryl Compounds | 2020 |
Effect of 6-hydroxydopamine increase the glutathione level in SH-SY5Y human neuroblastoma cells.
Topics: Antioxidants; Cell Line, Tumor; Cysteine; Glutathione; Glutathione Disulfide; Humans; Ligases; Neuroblastoma; Oxidopamine; Reactive Oxygen Species | 2023 |